Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May 2;5(5):e2210880.
doi: 10.1001/jamanetworkopen.2022.10880.

Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis

Emma Khoury  1   2 , Sarah Nevitt  3 , William Rohde Madsen  4   5 , Lance Turtle  6 , Gerry Davies  7   8 , Carlo Palmieri  1   9
Affiliations
Meta-Analysis

Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis

Emma Khoury et al. JAMA Netw Open. .

Abstract

Importance: SARS-CoV-2 infection has been associated with more severe disease and death in patients with cancer. However, the implications of certain tumor types, treatments, and the age and sex of patients with cancer for the outcomes of COVID-19 remain unclear.

Objective: To assess the differences in clinical outcomes between patients with cancer and SARS-CoV-2 infection and patients without cancer but with SARS-CoV-2 infection, and to identify patients with cancer at particularly high risk for a poor outcome.

Data sources: PubMed, Web of Science, and Scopus databases were searched for articles published in English until June 14, 2021. References in these articles were reviewed for additional studies.

Study selection: All case-control or cohort studies were included that involved 10 or more patients with malignant disease and SARS-CoV-2 infection with or without a control group (defined as patients without cancer but with SARS-CoV-2 infection). Studies were excluded if they involved fewer than 10 patients, were conference papers or abstracts, were preprint reports, had no full text, or had data that could not be obtained from the corresponding author.

Data extraction and synthesis: Two investigators independently performed data extraction using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Meta-analysis was performed using a random-effects model.

Main outcomes and measures: The difference in mortality between patients with cancer and SARS-CoV-2 infection and control patients as well as the difference in outcomes for various tumor types and cancer treatments. Pooled case fatality rates, a random-effects model, and random-effects meta-regressions were used.

Results: A total of 81 studies were included, involving 61 532 patients with cancer. Among 58 849 patients with available data, 30 557 male individuals (52%) were included and median age ranged from 35 to 74 years. The relative risk (RR) of mortality from COVID-19 among patients with vs without cancer when age and sex were matched was 1.69 (95% CI, 1.46-1.95; P < .001; I2 = 51.0%). The RR of mortality in patients with cancer vs control patients was associated with decreasing age (exp [b], 0.96; 95% CI, 0.92-0.99; P = .03). Compared with other cancers, lung cancer (RR, 1.68; 95% CI, 1.45-1.94; P < .001; I2 = 32.9%), and hematologic cancer (RR, 1.42; 95% CI, 1.31-1.54; P < .001; I2 = 6.8%) were associated with a higher risk of death. Although a higher point estimate was found for genitourinary cancer (RR, 1.11; 95% CI, 1.00-1.24; P = .06; I2 = 21.5%), the finding was not statistically significant. Breast cancer (RR, 0.51; 95% CI, 0.36-0.71; P < .001; I2 = 86.2%) and gynecological cancer (RR, 0.76; 95% CI, 0.62-0.93; P = .009; I2 = 0%) were associated with a lower risk of death. Chemotherapy was associated with the highest overall pooled case fatality rate of 30% (95% CI, 25%-36%; I2 = 86.97%; range, 10%-100%), and endocrine therapy was associated with the lowest at 11% (95% CI, 6%-16%; I2 = 70.68%; range, 0%-27%).

Conclusions and relevance: Results of this study suggest that patients with cancer and SARS-CoV-2 infection had a higher risk of death than patients without cancer. Younger age, lung cancer, and hematologic cancer were also risk factors associated with poor outcomes from COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Turtle reported receiving personal fees paid to the University of Liverpool from Eisai Ltd. Dr Palmieri reported receiving grants from Pfizer and Daiichi Sankyo as well as personal fees from Pfizer, Roche, Daiichi Sankyo, Novartis, Exact Sciences, Gilead, SeaGen, and Eli Lilly outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Forest Plot of Relative Risk (RR) of Mortality
Weights were calculated using random-effects analysis. REML indicates restricted maximum likelihood.
Figure 2.
Figure 2.. Meta-regression Bubble Plot of Association of Mortality With Age and Sex of Patients vs Control Group
Figure 3.
Figure 3.. Forest Plot of Overall Case Fatality Rate for Surgery, Chemotherapy, and Endocrine Therapy
ES indicates effect size.
Figure 4.
Figure 4.. Forest Plot of Overall Case Fatality Rate for Immunonotherapy, Radiotherapy, and Targeted Therapy
ES indicates effect size.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chemaly RF, Vigil KJ, Saad M, et al. . A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer. 2012;118(18):4627-4633. doi:10.1002/cncr.27447 - DOI - PubMed
    1. Dignani MC, Costantini P, Salgueira C, et al. . Pandemic 2009 influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000Res. 2014;3:221. doi:10.12688/f1000research.5251.1 - DOI - PMC - PubMed
    1. Campbell AP, Guthrie KA, Englund JA, et al. . Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192-202. doi:10.1093/cid/civ272 - DOI - PMC - PubMed
    1. Docherty AB, Harrison EM, Green CA, et al. ; ISARIC4C investigators . Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi:10.1136/bmj.m1985 - DOI - PMC - PubMed
    1. Richards-Belle A, Orzechowska I, Gould DW, et al. ; ICNARC COVID-19 Team . COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. Intensive Care Med. 2020;46(11):2035-2047. doi:10.1007/s00134-020-06267-0 - DOI - PMC - PubMed

Publication types